Consumer and clinician perspectives on personalising breast cancer prevention information

被引:22
|
作者
Keogh, L. A. [1 ]
Steel, E. [1 ]
Weideman, P. [2 ,9 ]
Butow, P. [3 ,4 ]
Collins, I. M. [2 ,5 ]
Emery, J. D. [6 ]
Mann, G. B. [7 ,8 ]
Bickerstaffe, A. [9 ]
Trainer, A. H. [2 ,10 ]
Hopper, L. J. [9 ]
Phillips, K. A. [2 ,9 ,11 ]
机构
[1] Univ Melbourne, Ctr Hlth Equ, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[3] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making CeM, Sydney, NSW, Australia
[4] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW, Australia
[5] Deakin Univ, Greater Green Triangle Clin Sch, Sch Med, Warrnambool, Australia
[6] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia
[7] Royal Melbourne & Royal Womens Hosp, Breast Serv, Melbourne, Vic, Australia
[8] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia
[9] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[10] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Breast cancer prevention; Risk management; Online risk assessment; Focus groups; Clinician perspectives; Consumer perspectives; RISK; CARE; SUSCEPTIBILITY; GENOMICS; WOMEN; MODEL;
D O I
10.1016/j.breast.2018.11.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Personalised prevention of breast cancer has focused on women at very high risk, yet most breast cancers occur in women at average, or moderately increased risk ( <= moderate risk). Objectives: To determine; 1) interest of women at <= moderate risk (consumers) in personalised information about breast cancer risk; 2) familial cancer clinicians' (FCCs) perspective on managing women at <= moderate risk, and; 3) both consumers' and FCCs reactions to iPrevent, a personalised breast cancer risk assessment and risk management decision support tool. Methods: Seven focus groups on breast cancer risk were conducted with 49 participants; 27 consumers and 22 FCCs. Data were analysed thematically. Results: Consumers reported some misconceptions, low trust in primary care practitioners for breast cancer prevention advice and frustration that they often lacked tailored advice about breast cancer risk. They expressed interest in receiving personalised risk information using iPrevent. FCCs reported an inadequate workforce to advise women at <= moderate risk and reacted positively to the potential of iPrevent to assist. Conclusions: While highlighting a potential role for iPrevent, several outstanding issues remain. For personalised prevention of breast cancer to extend beyond women at high risk, we must harness women's interest in receiving tailored information about breast cancer prevention and identify a workforce willing to advise women. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 50 条
  • [41] Hormonal prevention of breast cancer
    Thomin, Anne
    Friszer, Stephanie
    Fajac, Anne
    Darai, Emile
    Chabbert-Buffet, Nathalie
    ANNALES D ENDOCRINOLOGIE, 2014, 75 (03) : 148 - 155
  • [42] Medical Prevention of Breast Cancer
    Stubert, Johannes
    Dieterich, Max
    Gerber, Bernd
    BREAST CARE, 2014, 9 (06) : 391 - 396
  • [43] Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information
    Nycum, Gillian
    Avard, Denise
    Knoppers, Bartha M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2009, 17 (07) : 872 - 880
  • [44] Exercise and Breast Cancer Prevention
    Bernstein, Leslie
    CURRENT ONCOLOGY REPORTS, 2009, 11 (06) : 490 - 496
  • [45] Retinoids and Breast Cancer Prevention
    Bonanni, Bernardo
    Lazzeroni, Matteo
    Cancer Prevention II, 2009, 181 : 77 - 82
  • [46] Breast Cancer Screening and Prevention
    Nattinger, Ann B.
    Mitchell, Julie L.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (11) : ITC81 - ITC94
  • [47] Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation
    Smith, Samuel G.
    Side, Lucy
    Meisel, Susanne F.
    Horne, Rob
    Cuzick, Jack
    Wardle, Jane
    PUBLIC HEALTH GENOMICS, 2016, 19 (04) : 239 - 249
  • [48] A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene
    Noonan, Silvia
    Pasa, Ambra
    Fontana, Vincenzo
    Caviglia, Silvia
    Bonanni, Bernardo
    Costa, Alberto
    Smith, Samuel G.
    Peccatori, Fedro
    DeCensi, Andrea
    CANCER PREVENTION RESEARCH, 2018, 11 (01) : 38 - 43
  • [49] Serum hormone concentrations and individualisation of breast cancer prevention
    Chumsri, Saranya
    LANCET ONCOLOGY, 2024, 25 (01) : 8 - 9
  • [50] Testosterone and breast cancer prevention
    Glaser, R.
    Dimitrakakis, C.
    MATURITAS, 2015, 82 (03) : 291 - 295